Assessment of the immune response to tumors is growing in importance as the prognostic implications of this response are increasingly recognized, and as immunotherapies are evaluated and implemented in different tumor types. However, many different approaches can be used to assess and describe the immune response, which limits efforts at implementation as a routine clinical biomarker. In part 1 of this review, we have proposed a standardized methodology to assess tumor-infiltrating lymphocytes (TILs) in solid tumors, based on the International Immuno-Oncology Biomarkers Working Group guidelines for invasive breast carcinoma. In part 2 of this review, we discuss the available evidence for the prognostic and predictive value of TILs in common solid tumors, including carcinomas of the lung, gastrointestinal tract, genitourinary system, gynecologic system, and head and neck, as well as primary brain tumors, mesothelioma and melanoma. The particularities and different emphases in TIL assessment in different tumor types are discussed. The standardized methodology we propose can be adapted to different tumor types and may be used as a standard against which other approaches can be compared. Standardization of TIL assessment will help clinicians, researchers and pathologists to conclusively evaluate the utility of this simple biomarker in the current era of immunotherapy.

中文翻译：

---

评估实体瘤中的肿瘤浸润淋巴细胞：病理学家的实践回顾和国际免疫肿瘤学生物标志物工作组标准化方法的提案：第 2 部分：黑色素瘤、胃肠道癌、非小细胞肺癌和间皮瘤中的 TIL，子宫内膜癌和卵巢癌、头颈鳞状细胞癌、泌尿生殖系统癌和原发性脑肿瘤。

随着人们越来越认识到这种反应的预后意义，并且随着免疫疗法在不同肿瘤类型中的评估和实施，对肿瘤免疫反应的评估变得越来越重要。然而，可以使用许多不同的方法来评估和描述免疫反应，这限制了作为常规临床生物标志物的实施工作。在本综述的第 1 部分中，我们根据国际免疫肿瘤学生物标志物工作组针对浸润性乳腺癌的指南，提出了一种评估实体瘤中肿瘤浸润淋巴细胞 (TIL) 的标准化方法。在本综述的第 2 部分中，我们讨论了 TIL 在常见实体瘤中的预后和预测价值的现有证据，包括肺癌、胃肠道癌、泌尿生殖系统癌、妇科系统癌、头颈癌以及原发性脑癌肿瘤、间皮瘤和黑色素瘤。讨论了不同肿瘤类型TIL评估的特殊性和不同侧重点。我们提出的标准化方法可以适应不同的肿瘤类型，并且可以用作比较其他方法的标准。TIL 评估的标准化将帮助临床医生、研究人员和病理学家最终评估这种简单生物标志物在当今免疫治疗时代的效用。